Dominovas Energy Corp. (OTCQB: DNRG) builds shareholder value by pursuing opportunity around advancing “NextGen” clean energy – an efficient, solid oxide fuel cell (SOFC) technology. Referenced within the energy industry as the RUBICON™, this trademark is designed by world-renowned scientist and engineer Shamiul Islam, PhD, along with engineers from AVL List GmbH.

Today’s market sees consumers spending their money on “Green Technology,” and for good reason. By “greening” residential communities, corporate offices, recreational parks, retail sites, industrial complexes, and distribution centers, governments and companies are demonstrating their commitment to their customers, employees, and local communities to reduce atmospheric pollutants. Fuel cells are front and center to this conversation – leading the charge into this new era of “Green Technology.”

The transition to fuel cell systems is in full swing among companies worldwide. In the 2008 Fuel Cell Technologies Market Report, it was stated that “Green” companies are retaining old customers and attracting new ones. It has also been widely reported that fuel cells have an unmistakably positive impact on our environment.

Global concerns about climate change, energy security, and air pollution are driving demand for fuel cell technology. It has been reported that over 630 companies and laboratories in the United States are investing over $1 billion a year in fuel cells or fuel cell component technologies, according to Fuel Cells 2000. Major grocery chains, hotels, distributors, telecom companies, manufacturers, and many others that implement fuel cell systems are finding them to be exceptionally efficient and cost effective.

Dominovas Energy Corporation has designed the first of its kind “mega-watt true” fuel cell system and will manufacture, market, and deploy multi-megawatt power plants driving the production of ‘green technologies.’ Today, the company offers the RUBICON™ fuel cell system, a modular SOFC system that operates at high temperatures and offers its products to the fuel cell and sustainable/alternative energy industry. Dominovas Energy Corporation is headquartered in Atlanta, Georgia.

For more information, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Earlier today, Avant Diagnostics, Inc. (OTCQB: AVDX) announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Avant will be provided with a 30-minute time slot with which to present to an audience of investors and industry professionals. The company’s management team is also expected to be available for one-on-one meetings with institutional investors attending the event.

To view a complete list of presenting companies, visit http://steconference.com/presenting-companies

This announcement follows last month’s news that Avant has entered into a letter of intent to merge with Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS). The proposed merger is expected to create opportunities for the combined company to progress the development of highly valuable diagnostic assets – including Avant’s OvaDx® large panel biomarker test for use in monitoring women at a heightened risk for ovarian cancer, as well as Amarantus Diagnostics’ MSPrecise® diagnostic assay for multiple sclerosis and LymPro Test® flow cytometry assay for Alzheimer’s disease.

“After exploring numerous avenues for implementing Avant’s OvaDx® development and commercialization strategy, it is clear that combining Avant’s and Amarantus’ diagnostic assets and core competencies forms a platform that provides maximum value to our collective shareholders,” Gregg Linn, president and chief executive officer of Avant, stated in a recent news release. “The collective diagnostic assets will create a truly unique opportunity to implement our respective missions of saving and enhancing lives through early detection of disease in oncology and neurology.”

SeeThruEquity, a leading independent equity research and corporate access firm, released a report studying the potential effects of the Avant merger last month. Among the highlights, the SeeThruEquity report inferred that, when completed, the proposed merger “will allow them to progress at a much faster pace and to develop valuable diagnostic assets in areas of oncology and neurology.” The report went on to note that the combined assets of Avant and Amarantus Diagnostics “have the potential to improve the practice of medicine by providing new proprietary diagnosis and monitoring tools for oncologists and neurologists.”

If approved for commercialization, OvaDX, in particular, is expected to offer a clear improvement to the current diagnostic standard by substantially improving the accuracy of diagnosis and allowing for a more effective therapeutic triaging and intervention strategy. It’s estimated that the market opportunity for OvaDx is $50 million annually as a diagnostic test for ovarian cancer, and this opportunity would expand to over $2 billion annually if it were to be approved as a generalized screening and/or monitoring tool.

For more information, visit the company website at www.avantdiagnostics.com

Let us hear your thoughts: Avant Diagnostics, Inc. Message Board

Experience is an invaluable asset. In business and life in general, there is no substitute for relevant experience. Education is very important, but a seasoned veteran with a wealth of time doing the various tasks associated with running a successful business and the connections that come with someone like this are indispensable. Giggles N’ Hugs, Inc. (OTCQB: GIGL) has this type of management experience steering its ship through the ‘Restaurant Channel’, so to speak. Both President John Kaufman and CFO Phillip Gay have impressive track records of success that warrant attention and praise.

John Kaufman was the COO of California Pizza Kitchen when its founders only had two locations. He was responsible for helping it grow from two locations to more than 100 locations before Pepsico, Inc. (NYSE: PEP) acquired it. Once that successful venture was complete, he was hired as the President of Koo Koo Roo Chicken, one of the fastest growing chicken franchises on the west coast.

An operational, creative guru like John Kaufman could not do it without someone to balance the books and spearhead the all important numbers aspect of a successful business. Phillip Gay was the CFO of California Pizza Kitchen and then later was CFO of the incredibly popular, high-end Wolfgang Puck Restaurants franchise, where he eventually became the CEO.

Giggles N’ Hugs is a first-of-its-kind, award-winning family restaurant and play space that combines organic gourmet food with engaging play elements for children, with a 2,500-square-foot play space in the middle of the restaurant. The concept is similar to Chuck E. Cheese, but Giggles N’ Hugs offers a unique, healthier, high-end version for health conscious parents and families. Parents eat and relax while the kids have an incredible time playing in the custom-made play area with giant climbers, dragons, castles, pirate ship slides and swings and a multitude of other toys.

In addition to nightly shows and concerts, every 30 minutes Giggles N’ Hugs provides an activity such as face painting, disco dance parties, karaoke, games, arts and crafts, and much more. Giggles N’ Hugs has been voted the No. 1 family restaurant, No. 1 birthday party place, and the No. 1 indoor play space in all of Los Angeles, and it has attracted a star-studded list of customers including Sandra Bullock, Heidi Klum, Jessica Alba, Halle Berry, Jennifer Garner and Ben Affleck, Dennis Quaid, Mark Wahlberg, Adam Sandler, Dustin Hoffman and many more.

Learn more by visiting www.gigglesnhugs.com

Let us hear your thoughts: Giggles ‘N Hugs, Inc. Message Board

Viruses are constantly mutating, taking on new and daunting characteristics which make it more and more difficult for medical science to thwart them, especially when the only tools available are based on centuries old technology. The growing concern over the Zika virus, for instance, with nearly 4,500 confirmed cases in Brazil (http://dtn.fm/80KgF) and cases cropping up here in the U.S. (http://dtn.fm/iJe94), has lit a fire under the biotech sector, but a hoped-for vaccine could only be partially effective at fighting the spread. President Barack Obama recently asked Congress for $1.8 billion in emergency funding that would, in part, help expedite the development of a Zika vaccine. While Inovio Pharmaceuticals (NASDAQ: INO) has shown positive signs (http://dtn.fm/dngJ3) with its nascent vaccine, human trials won’t see the light of day until the end of this year.

The real kicker, though, is that, even if a vaccine is developed, it may be only marginally effective at stopping something like Zika, which is now even more readily asserted to be sexually transmissible (http://dtn.fm/7KlhH), directly linked to microcephaly (http://dtn.fm/0zI3B) in the newborn infants of infected women and even the paralyzing Guillain-Barre syndrome (http://dtn.fm/IP1kw). As is the case with seasonal influenza (flu) vaccines, overall efficacy is the real bottom line, and the CDC’s own numbers (http://dtn.fm/Czzi9) indicate that for the 2014 to 2015 season, adjusted overall efficacy was a mere 23 percent.

What we really need here is something new – a new and more agile weapon system based on truly 21st century technology. Development-stage NanoViricides (NYSE MKT: NNVC), with its nanotechnology-based biomimetic anti-viral medicines called nanoviricides® looks to be the answer to a question that, sadly, many in the medical community aren’t even asking yet. This technology could rightly be considered a “penicillin” for viruses due to the breadth of application, speed with which new indications can be developed, and show-stopping efficacy potential, and the company’s proprietary nanoviricides are also able to be administered orally (as well as through injection) in certain cases. Oral FluCide™, for instance, which NNVC proudly proclaims to be the first ever oral nanomedicine, has been shown to be substantially superior (http://dtn.fm/Ef7RD) to Roche’s (OTC: RHHBY) TamiFlu® (Oseltamivir) in animal models (Totally Lethal Infection Study) and exhibited broad-spectrum efficacy (Influenza A H1N1 and H3N2). Oral Flucide has also shown clear indication that a full clinical recovery is possible, even in high path, severe influenzas.

NanoViricides has received the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector from the prestigious IAIR® Group, the Milan-headquartered research institute and independent publishing house with major shareholders from Europe and Asia which has over a decade in global economy and sustainability publishing. This revolutionary company has developed a simple, yet powerful, antiviral platform technology employing the combination of a nanomicelle polymer that engulfs the target cell (http://dtn.fm/L2pcG), and mimic receptor proteins known as ligands, which lure the targeted virus to attack the nanoviricide. This platform’s key advantage of being able to trick the targeted virus into thinking the nanoviricide is a normal human cell via the ligands, which do not substantially change even when a virus mutates to a new form that may be resistant to other measures, is reinforced ably by NNVC’s proprietary method for quickly creating the unique ligands which are used. Because of this sweeping unification of efficacy and developmental capabilities, nanoviricides are not only suitable for attacking otherwise impossible to defeat viral agents on a commercial scale, they can also be rapidly developed in the field as a frontline measure to combat fast-mutating viruses using the company’s ADIF™ (Accurate-Drug-In-Field) technology.

Because the technique for field developing targeted therapeutics using ADIF involves the same tried and tested methodology as for any other nanoviricide – deriving the virus-binding ligand from the binding site of the virus cell surface receptor – the capacity to create an effective, targeted therapeutic in the midst of an outbreak, with only a small lab setup, is an advantage moving forward for NNVC that represents a tremendous value proposition to investors. Additionally, since the ADIF technology does not require any specific identification of the actual virus or difficult to obtain understanding of the specific molecular biology of the pathogen in question, a rapid-deployment nanoviricide, made using nanomicelles that have been stockpiled beforehand, effectively constitutes a field-ready smart weapon that is as adaptable as the most daunting viruses in existence, such as H5N1, SARS, and Ebola.

The combined market size for injectable and oral FluCide is likely over $30 billion, and because the company’s antivirals are so completely focused by design on the target virus, there is virtually no impact to the host, marking another clear advantage of this technology over antiquated vaccine technology. These nanoviricides can be created in weeks, instead of the years often required to develop a vaccine, and the company already has a robust pipeline of six potential blockbusters that have been tested in over 6,000 animals. FluCide has produced some amazing results thus far in animal model work, such as a greater than 1,000-fold lung viral load reduction, compared to less than two-fold in TamiFlu and the control group, or 100 percent survival rate at 22 plus days seen in the Totally Lethal Infection Study, compared to a 100 percent death rate after only eight days with extended TamiFlu treatment (100 percent death rate after five days with control group).

The combined estimated market size for the company’s antiviral eye drops designed to fight conjunctivitis/keratitis, its HerpeCide™ indication for shingles, as well as ocular and genital herpes (note that HSV-1 has also been linked to Alzheimer’s), and its DengueCide™ indication to combat Dengue arboviruses (West Nile, Yellow Fever, Japanese B Encephalitis), are in the neighborhood of $17 billion. The market size for NNVC’s HivCide™, which could be the first ever broad-spectrum weapon to stop the spread of HIV/AIDS, is estimated to be around $22 billion. The company’s DengueCide indication for Dengue fever and Dengue hemorrhagic fever is of particular note here, as that virus is in the same family as Zika.

The company already has multiple pre-clinical studies underway at various universities, HerpeCide is on track for human trials as early as this year, FluCide is slated for human trials shortly thereafter, and both the FDA and EMA have granted DengueCide orphan drug status. To understand the full story of NNVC, though, it is important to look at the company’s visionary management, including its chairman and president, Anil R. Diwan, PhD, as well as its CEO, Eugene Seymour MD, MPH, and CSO, Randall W. Barton, PhD.

Dr. Diwan, a prolific inventor and serial entrepreneur, pioneered polymeric micelle-based nanomedicine technologies with his invention of them back in 1991, but he is also the driving force behind keeping the company’s administrative and R&D costs at extremely low levels – despite the fact that the company has been aggressively expanding its pipeline each year. This administrative acumen is due in large part to his considerable wealth of experience, having founded nanomedicine and cell-targeted drug delivery, as well as small chemical, device technology and informatics-focused operations such as TheraCour Pharma and AllExcel, prior to co-founding NNVC. Dr. Diwan is a patent holder, with three more applications filed internationally resulting in numerous nation-level patents abroad. He has received numerous NIH small business innovation research grant awards and has several patent applications in various stages.

Dr. Seymour has a similarly eminent history of research and work under his belt, having cut his teeth back in the 1960’s in LA and Beverly Hills during the rise of the HIV/AIDS epidemic and having been tapped by the U.S. government to create a testing laboratory, as well as run a large-scale data generation operation examining HIV prevalence in LA’s Hispanic population. Dr. Seymour founded the company now known as Stat-Sure because of his foresight about the importance of prevention in lieu of a cure for HIV, and he went on to run a large non-profit after leaving the company in the late 1990’s, spearheading testing and training efforts in Asia and Africa before going on to be a UN Global Program on AIDS consultant who was deployed in several other countries. A holder of eight patents whose first love was chemistry and who initially trained to be a clinical investigator, Dr. Seymour got his master’s degree in the epidemiology of infectious diseases from UCLA before going on to do internal medicine work, and later becoming a member of the USC faculty as an Associate Professor. Dr. Seymour is also a Vietnam vet, having served in the U.S. Army Reserve Medical Corps during the Vietnam era, attaining the rank of Major.

Last, but certainly not least, is NNVC chief science officer Dr. Barton. Dr. Barton, former VP of drug discovery at personalized oncology innovators A&G Pharmaceuticals, has a rich history of drug discovery and development on both the small molecule and biological drug candidate ends of the spectrum, spanning multiple focus areas from virology and immunology to inflammation. Dr. Barton also possesses a great deal of experience in cardiovascular disease-related discovery and development from his collective pharmaceutical/biotech industry work, and he was a director for two decades at the U.S. pharmaceuticals division of German pharma giant Boehringer Ingelheim, where he helped do the pre-clinical development on the important HIV inhibitor drug Viramune (Nevirapine). This is a man with over 80 scientific publication to his name who has an abundance of academic and teaching experience behind him and who was the principal investigator in the development of five patents. Dr. Barton received his PhD in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and was a faculty member at the University of Connecticut Medical School when he was awarded the NIH’s Career Development Award for his work doing research and education in the field of immunology.

Needless to say, NNVC has an esteemed, deep bench of upper management talent that has continued to produce bottom line results and mounting shareholder value in the form of its candidate portfolio. The immense potential of the company’s rapidly developing pipeline and nanoviricide/ADIF platform technologies themselves cannot really be properly estimated. Investors need to take a closer look here before the rest of the world realizes what NNVC has its hands on.

Get ahead of the curve, visit www.nanoviricides.com

Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) is on a mission to bring jobs back to the United States while commercializing stored energy solutions that meet the stringent quality standards necessary to power state-of-the-art technologies in a variety of expansive and growing industries. The company’s innovative ‘Made in the USA’ product line already includes multiple lithium-ion chemistries, technologies and form factors that are optimized to address four high-demand target markets – including motive applications, such as electric and hybrid electric fleet vehicles; stationary living space power for domestic, commercial and grid applications; remote control and portable devices; and starter motor batteries for motorcycles, jet skis, snowmobiles, boats, cars and trucks. Through these offerings, Oakridge targets major applications in the military, aerospace, marine, medical and telecom sectors, among others.

Under the guidance of an experienced management team, Oakridge is strategically positioned to achieve tremendous growth in the months to come. In January, the company announced the sale of its interest in Leclanché S.A., attaining the funds needed to satisfy a long-standing loan from Expedia Holdings Limited and entering 2016 completely debt-free and funded for growth. Shortly after this transaction, Oakridge entered into the full scale production phase of its corporate restructuring efforts, kick starting solid revenues that are expected to grow rapidly throughout the first quarter of 2016 and beyond.

“We are now well on our way to becoming a major player in the world lithium-ion battery manufacturing space,” Steve Barber, executive chairman and chief executive officer of Oakridge, stated in a January news release. “The addition of this significant capital into Oakridge provides the liquidity that we needed to launch this company from small scale production to one of the largest lithium battery manufacturing facilities in the world.”

As the company continues to exceed target goals for hiring of employees, acquisition of capital equipment for factory automation and introduction of informative tools designed to increase shareholder engagement and overall brand awareness, Oakridge is aggressively serving its target markets and engaging with the global lithium battery market. Look for Oakridge to continue benefitting from the expanded capacity offered by its new 69,000-square-foot facility in Melbourne, Florida, as it intensifies efforts to increase market share and roll out exciting new product lines moving forward.

For more information, visit www.oakridgeglobalenergy.com

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

Back in 2001, Ms. Gay, a frail 85-year-old, was out walking her dog, Blue, in Florida. She slipped and, falling to the ground, couldn’t get up. It wasn’t long before her plight was noticed by a ‘gator. Alligators in Florida typically measure over eight feet and weigh about 800 lbs. The only thing standing between her and certain death was her little Australian Blue Heeler, weighing in at 24 inches and 50 lbs, which took up a position in the line of the advancing predator. Ms. Gay watched the encounter with terrified, unbelieving eyes as the dog dodged, again and again, the giant jaws that snapped shut as the ‘gator attacked and advanced. Blue continued his rearguard action as he retreated until, spying a breach in the enemy’s defense, he sprang in and ripped one of its eyes out. The reptile turned and fled.

Such remarkable valor and loyalty can only come from a well-developed intelligence and emotional capacity. Dogs are very intuitive and appear to be particularly able to sense our emotional state. Some possess an innate ability to detect the onset of an epileptic seizure, hours before symptoms are experienced. With their keen sense of smell, they can ascertain subtle chemical changes in perspiration that signal distress or malfunction. Diabetes alert dogs can assist sufferers of hypoglycemia, which affects mostly people with type 1 diabetes, because they sense when their owner’s blood sugar is dropping rapidly or is dangerously low. But having a mind has a downside, too. Just like us, cats and dogs can become bored. Just like us, they require mental stimulation. When the Roman poet, Juvenal, prayed for a healthy mind in a healthy body (mens sana in corpore sano), his entreaty might have been for our feline and canine friends as well.

OurPet’s Company (OTCQX: OPCO) has been demonstrating its progressive attitude toward pets by recognizing their mental facets. Its approach has always been based on thoughtful analysis, not only of their physical well-being and safety, but their cognitive expression and emotional equilibrium. For example, it has developed a large (4-inch) IQ Treat Ball® that can be adjusted to suit a dog’s learning grade. The Treat Ball is filled with goodies which can only be obtained if the canine is able to discover the way in. To do so, it must uncover the hatches and apertures on the surface of the ball. It’s motivated to do so by the smell of the treats and their sound as it moves the ball around. Built on the same concept but simpler is the Buster Food Cube. The Buster Food Cube is filled with treats, and a dog must turn it in a way that allows the treats to slip through a small circular hole on one side of the cube. Innovative products like these for dogs, and cats, constitute about 50 percent of OurPet’s Company’s revenues, which were $22.8 million in 2014. 2015 revenues are expected to be reported within the next few weeks.

A press release (http://dtn.fm/Vb98R) announcing the latest market study by the American Pet Products Association (APPA), the 2015–2016 National Pet Owners Survey, estimates that the average amount spent annually on toys for dogs is $47. The survey also reports that there are some 77.8 million pet dogs in the U.S. Putting these two numbers together suggests that the market for dog toys has the potential to reach $3.7 billion if every household with a dog spends the average. A similar computation for feline toys puts the market potential at around $2.4 billion. The APPA study estimated a U.S. pet cat population of 85.8 million and the average annual per cat expenditure at $28.

These are markets that OurPet’s Company is just beginning to scratch. It is marketing its wide variety of premium, innovative, quality toys and accessories specially designed to awaken pets’ natural instincts under the OurPets brand. There’s tremendous room for growth and OurPet’s Company is in gear to increase market share. The company has been growing at an annually compounded rate of over 6%, twice the industry rate. OurPet’s Company’s strategic business plan calls for annual year-over-year sales growth of 15%-20% with targeted net income as a percentage of sales in the 10%-12% range. OurPet’s Company, with its innovative energy, is beginning to look like the Apple (NASDAQ: AAPL) of the pet toy industry.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

A pioneer in developing digital commerce technologies, Alternet Systems, Inc. (OTCQB: ALYI) aims to transform the electronic payment infrastructure that is so popular today. The company sees a bright future of global access to efficient and affordable banking and payment services. To align itself with this ever-increasing trend, Alternet Systems continues to develop advanced predictive data analytics applications for the mass consumer, telecommunications, and financial sectors, which have high growth markets. These applications include cutting-edge payment and financial solutions.

According to Andrew Mann, customer data director at the Co-Operative Group speaking at the Big Data and Analytics Retail Conference in London, successful companies know the power of data and use it to create a better experience for customers. It’s important to develop integrated customer solutions from data-driven analytics technology to make better business decisions.

Fortunately, Alternet Systems has a powerful Data Analytics Division to provide clients with customer trends and marketing solutions. Henryk Dabrowski, the company’s CEO, predicts that this division will “ramp up” last year’s established preliminary revenue base in its digital commerce operations. The Data Analytics Division is currently developing cloud-based solutions that offer micro segmentation and predictive analytics for clients. These solutions include translatable audience insight into market opportunities, channel optimization through micro segmentation analysis that gives the opportunity for store, web, and mobile locations, and a Connected Experience which offers purchasing power. These analytic solutions allow clients to quickly understand data in order to orchestrate new activities across multiple functional areas such as web and e-market personalization, loyalty incentives, KPI, and more.

Data Analytics is one of the fastest growing business sectors today. In 2015 alone, Data Analytics had a market value of $125 billion. By continuously advancing its Data Analytics Division, Alternet intends to lead the digital commerce industry while creating accessible solutions for everyone.

For more information, visit www.alternetsystems.com

Let us hear your thoughts: Alternet Systems, Inc. Message Board

The recent announcement by Avant Diagnostics, Inc (OTCQB: AVDX) and Amarantus Bioscience Holdings, Inc (OTCQX: AMBS) of their intention to tie the knot is a message of cheer for women who may be at risk for ovarian cancer. It also promises a partnership that will aggressively pursue opportunities in the rapidly expanding molecular diagnostics (MDx) market. A summary (http://dtn.fm/w2IbO) of a report from industry consultants Grand View Research estimates global molecular diagnostics market size at over $4.8 billion in 2014 with the U.S. market accounting for over $2.0 billion of that, and, according to a story (http://dtn.fm/D86pl) in The Journal of Precision Medicine, Grand View Research predicts the market will grow ‘at a compound annual growth rate (CAGR) of 8.7 percent to hit $8.02 billion by 2020, up from $4.47 billion in 2013. The growth will largely be driven by the rapidly increasing focus on theranostics and precision medicine, as well as the continuing development of advanced cancer diagnostic technologies like next-generation sequencing.’ Theranostics and precision medicine describe therapies with an individualized approach.

A press release (http://dtn.fm/AfG4c) on the Amarantus website proclaimed the purpose of the proposed merger was to ‘assist Avant Diagnostics in bolstering its product development and commercialization resources to accelerate the monetization of the combined company’s product pipeline… by harnessing the power of biomarkers based in the immune system.’ So what is molecular diagnostic testing, and how does it go about harnessing the power of biomarkers?

Molecular diagnostic testing has become possible since the successful mapping of the genes of humans. Spanning a period of over a decade, the Human Genome Project (HGP), initiated in 1990, was an international research effort to sequence and map all of the genes – together known as the genome – of members of our species, Homo sapiens. Completed in April 2003, the HGP gave us the ability, for the first time, to read nature’s complete genetic blueprint for building a human being. Now armed with that knowledge, it is possible to be able to detect specific sequences in deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) that may be associated with disease.

Employing these insights, Avant Diagnostics’ OvaDx is the first large panel biomarker monitoring test for ovarian cancer. It measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may signal an abnormal process or a disease. A biomarker, also called a molecular marker or a signature molecule, may also be used to see how well the body responds to a treatment for a disease or condition.

The molecular diagnostics space has seen a lot of activity in recent times. A story (http://dtn.fm/npFh5) in GEN states that many startup MDx companies, especially the ones engaged in cancer detection, have been snapped up by the big boys. Roche (OTCQX: RHHBY) has been particularly spendthrifty. Last year, it acquired a majority stake in Foundation Medicine (NASDAQ: FMI) for $1.18 billion. The pharmaceutical giant also paid around $625 million for Ariosa Diagnostics, another $450 million for Iquum, $350 million for Genia Technologies and an undisclosed sum for Signature Diagnostics.

Roche wasn’t the only large player to jump into the fray. In 2014, Veracyte (NASDAQ: VCYT) purchased Allegro Diagnostics for $21 million; Myriad Genetics (NASDAQ: MYGN) bought Crescendo Bioscience for $245 million; bioMérieux (OTC: BMXMF) bought BioFire Diagnostics for $486 million and Rosetta Genomics (NASDAQ: ROSG) purchased PersonalizeDx for $2 million in cash plus stock. Large companies like Roche, Qiagen (NASDAQ: QGEN), Becton Dickinson (NYSE: BDX) and Abbott (NYSE: ABT) have recognized the potential of the MDx market. They’re looking for companies like Avant and Amarantus to unlock value. Soon, it may be time to put out the welcome mat.

For more information, visit the company website at www.avantdiagnostics.com

Let us hear your thoughts: Avant Diagnostics, Inc. Message Board

Before the opening bell, Nutra Pharma Corporation (OTCQB: NPHC) announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Nutra Pharma will be provided with a 30-minute time slot with which to present to an audience of investors and industry professionals. The company’s management team is also expected to be available for one-on-one meetings with institutional investors attending the event.

To view a complete list of presenting companies, visit http://steconference.com/presenting-companies

This announcement caps off what has been an eventful week for Nutra Pharma. On Tuesday, the biotechnology company announced the first of several growth steps expected to expand its core business strength, as well as its reach into important commercial markets. As part of this strategy, Nutra Pharma added Thomas W. Northrop, a member of New York-based management advisory and investment firm Tri-State Capital Partners, LLC, to its expanded management team. Northrop will serve as the company’s senior commercial development officer moving forward. From this position, he is expected to lead new marketing efforts in healthcare, governmental and military entities; aging athletes; and the elderly, as well as the completion of scientifically rigorous pain relief trials in multiple settings.

“The addition of Tom Northrop and TriState’s arrival as part of Nutra Pharma’s expanded management team are the first steps in the company’s growth strategy for 2016,” Rik J. Deutsch, chief executive officer of Nutra Pharma, stated in Tuesday’s news release. “With Tri-State’s support, we now have the tools and a depth of resources that will allow for expansion into multiple markets, as well as to help accelerate the development and deployment of our prescription drug candidates.”

Additional information regarding Nutra Pharma’s 2016 growth plans is expected to be announced in the coming weeks. With opioid abuse at record levels and heightened recognition of the potential dangers of misusing acetaminophen and non-steroidal anti-inflammatory drugs (NSAID), such as ibuprofen, the company will look to leverage its position in the biotechnology industry in order to capitalize on sizable global markets for innovative products addressing chronic pain.

Nutra Pharma operates as a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases – including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. The company also markets drug products for the treatment of chronic pain under the Nyloxin® and Pet Pain-Away brands.

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

On Wednesday, leading independent equity research and corporate access firm SeeThruEquity announced that it has initiated coverage on Immune Therapeutics, Inc. (OTCQB: IMUN) with a 12-month price target of $0.61. IMUN is a specialty pharmaceutical company engaged in the manufacture, distribution and marketing of proprietary therapies targeting chronic, life-threatening diseases through the activation of the body’s immune system. The company’s technology platform includes two unique immunotherapies – Methionine-Enkephalin (MENK) and Low Dose Naltrexone (LDN), which is marketed as Lodonal™. MENK is a revolutionary option of therapy for those diagnosed with various forms of cancer, while LDN, which was originally developed as a treatment for individuals with opiate and alcohol dependence, now has the potential to become a primary drug used to treat a variety of autoimmune disorders, cancers and HIV/AIDS.

To view the full SeeThruEquity report, visit http://dtn.fm/q0yOP

Key highlights from the SeeThruEquity report include an update on IMUN’s progress toward marketing LDN in a large and relatively untouched market, results from the company’s phase I and II clinical trials studying MENK as an innovative solution to the treatment of various forms of cancer, successful enrollment and completion of clinical trials studying Lodonal in Nigeria and the potential impact of IMUN’s recently completed agreement with KRS Global for the further development and future profitability of the company.

“Immune Therapeutics, Inc. products and therapies are designed to exploit the intrinsic power of the immune system to help improve treatment of cancer, HIV/Aids, chronic inflammatory diseases, and autoimmune diseases,” Ajay Tandon, chief executive officer of SeeThruEquity, stated in yesterday’s news release.

SeeThruEquity’s coverage builds on what has been an exciting start to 2016 for IMUN shareholders. Last month, the company, alongside its partner organizations, achieved a major milestone in the development of Lodonal when it announced completion of its 90-day bridging trial comprised of HIV-positive patients. Following completion, IMUN submitted data to Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) in connection with the anticipated approval of Lodonal as an immune booster to improve the health and wellbeing of those affected by HIV-positive status and others with similarly compromised immune systems.

“September’s bridging trial enrollment completion and the efficiency of ensuing trials facilitated our submission of the results supporting the NAFDAC New Drug Application for Lodonal™,” Noreen Griffin, chief executive officer of IMUN, stated in a January news release. “It’s the objective of IMUN… to advance science and drug development with the intention of positively impacting patients with serious unmet healthcare needs.”

For more information, visit www.immunetherapeutics.com